Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip W Iversen

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
SLAS Discovery : Advancing Life Sciences R & D|September 3, 2021
Addressing Unusual Assay Variability with Robust StatisticsJason Haelewyn, Philip W Iversen, Jeffrey R Weidner
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 26, 2018
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancerMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 29, 2016
Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response ModelMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
The AAPS Journal|February 2, 2019
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft StudiesMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
Journal of Biomolecular Screening|February 24, 2006
A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratioPhilip W Iversen, Brian J Eastwood, G Sitta Sittampalam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Elevated expression of angiogenin in prostate cancer and its precursorsTerrence M Katona, Blake Lee Neubauer, Philip W Iversen, et al.
International Journal of Toxicology|June 14, 2012
Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agentLorrene A Buckley, Atsushi Sanbuissho, James J Starling, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2003
Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionCarole J Boylan, Kristina Campanale, Philip W Iversen, et al.
Molecular Cancer Therapeutics|March 27, 2003
Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkeyNathalie Godinot, Philip W Iversen, Linda Tabas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2013
Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cellsSusan E Pratt, Sara Durland-Busbice, Robert L Shepard, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
SLAS Discovery : Advancing Life Sciences R & D|September 3, 2021
Addressing Unusual Assay Variability with Robust StatisticsJason Haelewyn, Philip W Iversen, Jeffrey R Weidner
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 26, 2018
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancerMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 29, 2016
Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response ModelMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
The AAPS Journal|February 2, 2019
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft StudiesMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
Journal of Biomolecular Screening|February 24, 2006
A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratioPhilip W Iversen, Brian J Eastwood, G Sitta Sittampalam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Elevated expression of angiogenin in prostate cancer and its precursorsTerrence M Katona, Blake Lee Neubauer, Philip W Iversen, et al.
International Journal of Toxicology|June 14, 2012
Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agentLorrene A Buckley, Atsushi Sanbuissho, James J Starling, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2003
Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionCarole J Boylan, Kristina Campanale, Philip W Iversen, et al.
Molecular Cancer Therapeutics|March 27, 2003
Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkeyNathalie Godinot, Philip W Iversen, Linda Tabas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2013
Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cellsSusan E Pratt, Sara Durland-Busbice, Robert L Shepard, et al.
Pageof 4